Rigel Pharmaceuticals (RIGL) Cash & Current Investments (2010 - 2026)

Rigel Pharmaceuticals' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $146.7 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 90.25% year-over-year to $146.7 million in Q1 2026; TTM through Mar 2026 was $146.7 million, a 90.25% increase from a year earlier, with the FY2025 full-year figure at $155.0 million, up 100.4% from the prior year.
• Cash & Current Investments slipped to $146.7 million in Q1 2026 per RIGL's latest filing, from $155.0 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $155.0 million in Q4 2025 and bottomed at $49.1 million in Q2 2024.
• The 5-year median for Cash & Current Investments is $77.1 million (2025), against an average of $84.7 million.
• Biggest YoY gain for Cash & Current Investments was 173.27% in 2022; the steepest drop was 53.42% in 2022.
• Year by year, Cash & Current Investments stood at $58.2 million in 2022, then fell by 2.19% to $56.9 million in 2023, then surged by 35.81% to $77.3 million in 2024, then jumped by 100.4% to $155.0 million in 2025, then declined by 5.34% to $146.7 million in 2026.
• Per Business Quant, the three latest RIGL Cash & Current Investments figures stand at $146.7 million (Q1 2026), $155.0 million (Q4 2025), and $137.1 million (Q3 2025).